Advertisement
Advertisement
U.S. markets close in 2 hours 6 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Exact Sciences Corporation (EXAS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
95.26-1.26 (-1.31%)
As of 1:54PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close96.52
Open96.80
Bid95.31 x 900
Ask95.48 x 1000
Day's Range94.66 - 96.89
52 Week Range89.65 - 159.54
Volume485,677
Avg. Volume1,382,792
Market Cap16.379B
Beta (5Y Monthly)1.31
PE Ratio (TTM)N/A
EPS (TTM)-5.27
Earnings DateNov 02, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est147.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for EXAS

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Exact Sciences Corporation
    Analyst Report: Exact Sciences CorporationExact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in liquid biopsy (blood-based) cancer screening.
    Rating
    Fair Value
    Economic Moat
    7 days agoMorningstar
View more
  • Insider Monkey

    11 Best Genomic Stocks to Buy Now

    In this article, we will take a look at the 11 best genomic stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Genomic Stocks to Buy Now. Genomics is a branch of biology that studies the structure, function, evolution, mapping, and editing of genomes, […]

  • Insider Monkey

    Should I Avoid EXACT Sciences Corporation (EXAS)?

    We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]

  • PR Newswire

    Exact Sciences schedules third quarter 2021 earnings call

    Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its third quarter 2021 financial results after the close of the U.S. financial markets on November 2, 2021. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.

Advertisement
Advertisement